Study summary

Another IDH1 pill kept most tumors from growing for three years

Safusidenib 3-year follow-up · Phase 2 · Reported 2026 (Targeted Oncology)

What was tested

Safusidenib, an IDH1 inhibitor designed to reach the brain, for IDH1-mutant glioma, in a Japanese study.

What they found

• Confirmed response rate was 51.9%.
• 79.1% were free of progression at 36 months.

What it means

Now in phase 3 trials for newly diagnosed grade 2 glioma and as maintenance after treatment.